CRVO CervoMed Inc. Insider Trading

Director Joshua S Boger acquires 955,414 shares of CRVO at $3.14 in $3.0M private placement allocation.

Joshua S Boger, a Director at CervoMed Inc., participated in a private placement transaction acquiring 955,414 shares at $3.14 on 2026-06-11, for a total value of $2,999,999.96. This allocation increased his non-derivative holdings from 840,451 shares to 1,795,865 shares, representing a 113.7% increase in his position. However, the current market price of $2.48 represents an -81.1% decline from the 52-week high of $13.13, and the stock has declined 45.2% over the past 90 days and 27.9% over the past 30 days. The company reported zero revenue in its latest quarter, a net loss of $7,964,158.00, annual revenue decline of 58.9%, and remains unprofitable. This private placement allocation does not reflect discretionary buying conviction, as it represents a structured investment vehicle arrangement rather than an open-market purchase decision.

CRVO CEO ALAM bought 21,600 shares at $8.46 in 2 transactions on 2025-11-17 for $182,736.00; stock -39.7% from 52-week high amid cluster buying.

CEO John J Alam purchased 21,600 shares across 2 separate transactions totaling $182,736.00 at $8.46 per share on 2025-11-17, shifting his holdings from a short position (-9,100 shares) to a long position (12,500 shares post-transaction). The purchase occurs while the stock trades -39.7% from its 52-week high of $14.29, following a +14.8% move over 30 days. This buy is part of a cluster pattern with 3 other insiders also purchasing within the past 14 days, though all 4 of Alam's prior same-ticker trades (2025-11-12 through 2025-11-14) remain unmeasurable in outcome. The company posted revenue of $322,569.00 (latest quarter) against net income of $-7,726,639.00 and remains unprofitable on a full-year basis, while annual revenue growth stands at +36.3%. The rapid succession of insider purchases combined with the company's unprofitable state and significant distance from recent highs merits investor attention to both the underlying fundamentals and the pattern of insider accumulation.

CervoMed CCO Winton Matthew bought 5,000 shares ($41.4K) in 2 transactions at $8.43 and $7.95 on Nov 17–18, with 3 other insiders buying within 14 days

Winton Matthew, Chief Commercial and Business at CervoMed (CRVO), executed 2 separate purchases totaling 5,000 shares ($41.4K) at an average of $8.29, increasing his holdings by 50.0% from 10,000 to 15,000 shares. The purchases occurred on November 17–18 at prices below the current market price of $8.62, and notably, 3 other insiders also bought within the past 14 days, forming a cluster pattern. CervoMed remains unprofitable on a full-year basis with net income of $-7.7M but shows recent revenue growth of 36.3% on a quarterly revenue of $322.6K; the stock is currently trading 39.7% below its 52-week high of $14.29. This cluster activity from multiple insiders at a small-cap, unprofitable company signals shared internal perspective on valuation or opportunity, though the company's negative earnings and early-stage revenue profile warrant deep review.

Director Gregoire Sylvie buys 21,600 shares at $8.46 for $182,736.00; cluster of 4 insider buys in 14 days at unprofitable biotech.

Gregoire Sylvie, Director at unprofitable biotech CervoMed Inc. (net income: $-7.7M), completed 2 separate purchases on 2025-11-17 totaling 21,600 shares for $182,736.00 at a blended average price of $8.46. This follows 4 prior buys by the same insider at CRVO within the past 5 days (2025-11-12 through 2025-11-14), and coincides with a broader cluster in which 3 other insiders also bought within the past 14 days. The transaction occurred while the stock traded 39.7% below its 52-week high, though 30-day momentum is positive at +14.8%. The post-transaction holding of 12,500 shares indicates accumulation by this director despite the company's ongoing unprofitability ($-7.7M net income in the latest quarter) against the backdrop of strong revenue growth of +36.3% year-over-year. The cluster pattern and sustained buying by the same insider across consecutive days warrant attention to whether insiders perceive current valuation as attractive or whether external developments are driving coordinated accumulation.

CFO William Robert Elder buys 3,500 shares ($29.2K) across 2 transactions at CervoMed; 3 other insiders also bought within 14 days.

William Robert Elder, CFO, General Counsel & Secretary, executed 2 separate purchases totaling 3,500 shares for $29,250.00 at an average price of $8.36, increasing his holdings by 38.9% from 9,000 to 12,500 shares. This activity is part of a cluster pattern: 3 other insiders also bought within the past 14 days, suggesting coordinated confidence at current levels. However, Elder's personal track record across other holdings shows mixed outcomes: his prior cross-ticker buys averaged a 30-day return of -15.8% and a 90-day return of -20.3%, with a 50% win rate. At CervoMed specifically, his prior 2 completed buys posted a 90-day timing pattern of 1 out of 2 well-timed, with outcomes ranging from +11.1% to -51.8% over 90 days. The company is unprofitable (net income: $-7.7M in the latest period), though annual revenue is growing at +36.3%, creating a tension between growth trajectory and near-term losses that may warrant scrutiny of the cluster buy's durability.

CEO John J Alam buys 7,847 shares at blended $7.53 ($59.1K); stock +16.0% in 30d, cluster buy pattern with 3 other insiders in past 14 days

John J Alam, CEO & President, executed 3 separate purchases totaling 7,847 shares for $59,101.11 at an average price of $7.53 between November 13–14, 2025. The timing coincides with a broader cluster pattern: 3 other insiders also bought within the past 14 days. The stock has appreciated 16.0% over the prior 30 days and is currently trading at $8.21, representing a 9.0% gain from the blended transaction price. However, the company remains unprofitable with a net income of $-7.7M in the latest quarter, though annual revenue growth stands at +36.3%. Prior trades at this ticker lack measurable 90-day outcomes, limiting confidence in whether this activity reflects durable conviction or routine portfolio activity.

Chief Commercial Officer Winton Matthew buys 10,000 shares of CRVO at $7.57; cluster pattern with 3 others in 14 days

Winton Matthew, Chief Commercial and Business officer, purchased 10,000 shares at $7.57 on 2025-11-14, establishing an initial position. The transaction is part of a broader cluster pattern in which 3 other insiders also bought within the past 14 days, suggesting coordinated or contextually-aligned acquisition activity. However, the company is unprofitable with net income of $-7.7M in the latest fiscal year, though it shows annual revenue growth of +36.3%, and the stock currently trades at $8.21, down -42.6% from its 52-week high of $14.29. The insider's cross-ticker track record consists of only 1 prior buy, limiting inference about pattern consistency. Investors should monitor whether this multi-insider buying aligns with strategic fundamentals or represents conviction in a turnaround trajectory at an unprofitable growth-stage company.

Director Gregoire Sylvie purchased 7,847 shares at blended average $7.53 across 3 transactions; 3 other insiders also bought within 14 days.

Gregoire Sylvie, a Director at CervoMed Inc., executed 3 separate purchases totaling 7,847 shares for $59,101.11 between November 13–14, 2025, at prices ranging from $7.51 to $7.57. This filing reflects a cluster pattern: 3 other insiders also purchased shares within the past 14 days, suggesting coordinated confidence. However, the company's fundamentals present a mixed picture—while annual revenue growth reached +36.3%, the company posted a net loss of $-7.7M on quarterly revenue of $322.6K and remains unprofitable on a full-year basis. The stock currently trades at $8.21, up 16.0% over 30 days but down 42.6% from its 52-week high of $14.29. The insider's post-transaction holdings total 1,693 shares, indicating a position built through recent purchases rather than a long-established stake. The cluster buy pattern merits observation, though the underlying financial distress and recent share price volatility underscore fundamental execution risks.

CFO William Robert Elder buys 3,500 shares of CervoMed (CRVO) at $7.44 as stock trades -49.3% from 52-week high; cluster buy detected.

CFO William Robert Elder purchased 3,500 shares at $7.44 on 2025-11-12, increasing his holdings by 63.6% to 9,000 shares total. The timing is notable: the stock currently trades at $7.25, down 49.3% from its 52-week high of $14.29 and down 28.4% over the past 90 days. However, Elder's own prior purchase history at CRVO shows mixed results—his last buy on 2025-05-14 delivered a -15.8% 30-day return and his August 2024 buy yielded a -51.8% 90-day return—suggesting limited predictive power. A cluster pattern exists, with 2 other insiders also buying within 14 days. The company remains unprofitable with a net loss of $7,726,639.00 over the latest fiscal year despite strong annual revenue growth of 36.3%, creating ambiguity about whether this accumulation reflects conviction in a turnaround or simply opportunistic buying at depressed levels.

CEO Alam bought 5,553 shares of CRVO at $7.35; stock down 49.3% from 52-week high, cluster of 2 other insider buys in past 14 days.

ALAM JOHN J (CEO & President) purchased 5,553 shares at $7.35 on 2025-11-12, increasing his holdings to 1,467,131 shares. This transaction occurs as CRVO trades at $7.25, down 49.3% from its 52-week high of $14.29 and down 28.4% over the past 90 days, reflecting material recent weakness. Notably, 2 other insiders also bought within the past 14 days, forming a cluster buy pattern. However, the company's fundamentals remain challenged: it reported a net loss of $-7.7M on quarterly revenue of $322.6K, with full-year profitability still negative despite annual revenue growth of 36.3%. The CEO's cross-ticker track record shows only 1 prior open-market buy (outcome not yet measurable), and his same-ticker history at CRVO is similarly limited, providing minimal context for assessing the significance of this purchase amid deteriorated valuation and ongoing losses.